Welcome to our dedicated page for Karyopharm Therapeutics SEC filings (Ticker: KPTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Karyopharm Therapeutics Inc. (KPTI) SEC filings page provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Karyopharm is a commercial-stage pharmaceutical company listed on the Nasdaq Global Select Market, and its filings detail financial results, financing arrangements and key corporate developments related to its oncology-focused business.
Among the most relevant documents for investors are Form 10-K annual reports and Form 10-Q quarterly reports, which summarize financial performance, risk factors and updates on Karyopharm’s commercial product XPOVIO (selinexor) and its clinical pipeline in multiple myeloma, endometrial cancer, myelofibrosis and diffuse large B-cell lymphoma (DLBCL). These periodic reports typically discuss revenue from U.S. XPOVIO net product sales and license and royalty revenue from partners, as described in the company’s public communications.
The company also files numerous Form 8-K current reports to describe material events. Recent 8-K filings referenced in the provided information include disclosures of quarterly financial results, strategic financing transactions involving senior secured term loans and 9.00% convertible senior notes due 2028 and 2029, and the issuance of equity and warrants in private placements. Other 8-Ks cover topics such as board changes, workforce reductions and the provision of “cleansing materials” to potential investors during financing discussions.
Investors tracking capital structure and liquidity can review exhibits to these filings, which describe credit and guaranty agreements, note purchase agreements, warrant terms and registration rights agreements. For governance and compensation matters, additional filings may include proxy statements and equity award disclosures, such as inducement grants reported under Nasdaq Listing Rule 5635(c)(4).
On this page, Stock Titan supplements raw EDGAR documents with AI-powered summaries that highlight the main points of lengthy filings, helping readers quickly understand changes in debt, equity, cash runway expectations, and updates on Karyopharm’s clinical and commercial programs. Real-time updates ensure that new 10-Ks, 10-Qs, 8-Ks and other forms appear as they are filed, while specialized views can surface insider-related forms such as Form 4 when available.
Karyopharm Therapeutics Inc. is registering for resale up to 2,805,688 shares of common stock previously issued or issuable to institutional investors. This includes 1,487,917 outstanding shares sold in an October 2025 private placement and 1,317,771 shares issuable upon exercise of accompanying warrants. The company will not sell any new shares under this prospectus and will not receive proceeds from any resale, although it would receive cash if the warrants are exercised at their $6.64 per share exercise price.
In the October 2025 private placement, Karyopharm sold common stock and warrants at $5.880706 per share and warrant for gross proceeds of about $8.75 million. The warrants are exercisable until the earlier of 30 days after announcement of top-line Phase 3 XPORT-EC-042 endometrial cancer trial results for selinexor or October 10, 2028, and are subject to beneficial ownership limits. Karyopharm remains a commercial-stage oncology company focused on its lead drug XPOVIO (selinexor).
Karyopharm Therapeutics Inc. filed a resale registration covering up to 2,805,688 shares of common stock to be offered from time to time by selling stockholders. The registered amount consists of 1,487,917 outstanding shares and 1,317,771 shares issuable upon exercise of outstanding warrants.
The company is not selling any securities in this offering and will not receive proceeds from sales by the selling stockholders. Karyopharm would receive cash only if holders exercise warrants for shares at the stated exercise price. The shares may be sold through various customary methods and at market or negotiated prices.
As context, 17,050,876 shares were outstanding as of October 30, 2025
Karyopharm Therapeutics (KPTI) filed an S-3 prospectus for a resale of up to 9,569,707 shares of common stock by selling stockholders. The registration covers 949,908 shares already issued in recent financing transactions, 956,885 shares issuable upon exercise of outstanding pre-funded warrants, 4,950,947 shares issuable upon exercise of outstanding warrants with a $6.64 exercise price, and 2,711,967 shares issuable upon conversion of 9.00% Senior Convertible Notes due 2028, subject to customary limits.
The company stated it will not receive proceeds from sales by selling stockholders. It would receive cash only upon any cash exercises of warrants. The shares may be sold from time to time using methods described under “Plan of Distribution.”
As context, shares outstanding were 17,050,876 as of October 30, 2025. Examples of registered resale allocations include Braidwell Partners Master Fund LP 2,134,699 and Entities affiliated with Highbridge Capital Management, LLC 2,843,292.
Karyopharm Therapeutics (KPTI) reported Q3 2025 results and flagged substantial doubt about continuing as a going concern. Revenue was $44.0 million (product $32.0 million; license/other $12.0 million, including Menarini milestones). Operating expenses fell year over year, but the company posted a net loss of $33.1 million and interest expense of $11.0 million in the quarter.
As of September 30, cash, cash equivalents and investments totaled $45.9 million. The balance sheet shows a senior secured term loan of $100.0 million, $116.0 million of 2029 convertible notes (principal), and a $73.5 million deferred royalty obligation. Management cited debt service, a minimum liquidity covenant and uncertain funding access in concluding there is substantial doubt about the company’s ability to continue as a going concern.
Subsequent to quarter-end (October 2025), the company executed financing transactions that included $27.5 million of new borrowings/convertible debt, $25.4 million of near-term payment deferrals, a temporary $15.0 million reduction of the minimum liquidity covenant, exchanges of 2025/2029 notes into equity and warrants, and a private placement raising ~$8.8 million.
Karyopharm Therapeutics (KPTI) furnished an 8-K announcing its financial results for the quarter ended September 30, 2025, and a previously announced, publicly available conference call to discuss the results and company updates.
The accompanying press release was furnished as Exhibit 99.1 and is incorporated by reference. The company noted that this information, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act.
Karyopharm Therapeutics (KPTI) reported an insider equity grant: EVP, CFO & Treasurer Lori Macomber received 43,650 restricted stock units (RSUs) on 10/15/2025 at a price of $0. The RSUs convert into common stock on a one-for-one basis and vest 100% on December 31, 2026. Following the award, her beneficial ownership stands at 54,316 shares. The reported share amounts reflect the company’s one‑for‑fifteen reverse stock split effected on February 25, 2025.
Karyopharm Therapeutics (KPTI) reported an executive equity award on a Form 4. EVP & Chief Commercial Officer Sohanya Cheng received 43,650 restricted stock units (RSUs) on 10/15/2025 at $0. The RSUs convert into common stock on a one-for-one basis and vest 100% on December 31, 2026. Following the award, Ms. Cheng beneficially owns 79,506 shares directly.
Karyopharm Therapeutics (KPTI) reported an officer equity grant. SVP, General Counsel & Secretary Michael Mano received 43,650 restricted stock units (RSUs) on 10/15/2025 at a price of $0. Each RSU converts into one share of common stock and vests 100% on December 31, 2026. Following the award, the reporting person beneficially owned 65,075 shares directly.
Karyopharm Therapeutics (KPTI) reported an insider equity award for its President and CEO, Richard Paulson, on 10/15/2025. He received 114,285 restricted stock units at $0 under the company’s 2022 Equity Incentive Plan. The RSUs convert into common stock on a one-for-one basis and vest 100% on December 31, 2026. Following the grant, Paulson’s beneficial ownership totaled 198,331 common shares, held directly. He is also listed as a director.
Karyopharm Therapeutics (KPTI) reported an insider equity grant on a Form 4. EVP, Chief Development Officer Stuart Poulton received 39,682 restricted stock units (RSUs) on 10/15/2025 under the company’s 2022 Equity Incentive Plan at a reported price of $0. The RSUs convert to common stock on a one‑for‑one basis and vest 100% on December 31, 2026.
Following the grant, his direct beneficial ownership was 67,392 shares. This filing documents a routine equity award to a company officer.